PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyDung T. Le, Luis A. Díaz, Jennifer N. Uram et al.|New England Journal of Medicine|2015Cited by 9.4k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T. Le, Luis A. Díaz, Jennifer N. Durham et al.|Science|2017Cited by 6.6k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon CancerChristine Ribic, Steven Gallinger, Daniel J. Sargent et al.|New England Journal of Medicine|2003Cited by 2.1k
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal CancerAlan P. Venook, Charles D. Blanke, Anthony B. El-Khoueiry et al.|JAMA|2017Cited by 891
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Hedy L. Kindler, Richard M. Goldberg, Donna Niedzwiecki et al.|Journal of Clinical Oncology|2010Cited by 840